Rezolute receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Rezolute Inc (RZLT)
Rezolute Inc stock price live, this page displays NASDAQ RZLT stock exchange data. View the RZLT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Rezolute Inc real time stock price chart below.
What Is the Rezolute Inc Stock Price Today?
The Rezolute Inc stock price today is 3.270.
What Is the Stock Symbol for Rezolute Inc?
The stock symbol for Rezolute Inc is "RZLT."
What Stock Exchange Does Rezolute Inc Trade On?
Rezolute Inc is listed and trades on the NASDAQ stock exchange.
Is Rezolute Inc a Good Stock to Buy?
Determining whether Rezolute Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RZLT quote. (ISIN: US76200L3096)
What Is the Rezolute Inc Stock Price Today?
The Rezolute Inc stock price today is 3.270.
What Is the Stock Symbol for Rezolute Inc?
The stock symbol for Rezolute Inc is "RZLT."
What Stock Exchange Does Rezolute Inc Trade On?
Rezolute Inc is listed and trades on the NASDAQ stock exchange.
Is Rezolute Inc a Good Stock to Buy?
Determining whether Rezolute Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RZLT quote. (ISIN: US76200L3096)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.225
3.340
52 wk Range
1.070
11.457
RZLT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.2253.340
52 wk Range
1.07011.457
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RZLT Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
5.875
Upside
+79.66%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Rezolute receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 13G Rezolute For: 11 May
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral
Analyst Ratings
7 Buy
3 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 5.875
(+79.66% Upside)
Rezolute Inc SWOT Analysis
Pipeline Progress | Explore Rezolute's promising clinical trials for ersodetug in hyperinsulinism and RZ402 for diabetic macular edema, with key results expected in 2025-2026. |
Financial Strength | Delve into Rezolute's robust financial position, with $118 million in cash and a strong current ratio, supporting ongoing clinical programs. |
Market Opportunities | Learn about Rezolute's potential in niche markets, including congenital hyperinsulinism and diabetic macular edema, with oral administration as a key advantage. |
Analyst Outlook | Discover varied analyst perspectives on Rezolute, with price targets ranging from $7 to $9, reflecting the company's growth potential in metabolic diseases. |
Earnings
Latest Release
May 12, 2026
EPS / Forecast
-0.16 / -0.18
Revenue / Forecast
-- / --
Compare RZLT to Peers and Sector
Metrics to compare | RZLT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRZLTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.3x | −3.3x | −0.5x | |
PEG Ratio | −0.15 | 0.30 | 0.00 | |
Price/Book | 3.0x | 4.7x | 2.6x | |
Price / LTM Sales | - | 28.9x | 3.1x | |
Upside (Analyst Target) | 68.2% | 84.3% | 54.9% | |
Fair Value Upside | Unlock | −5.4% | 7.1% | Unlock |
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Rezolute (RZLT) Stock Price Today?
The Rezolute stock price today is 3.270 USD.
What Stock Exchange Does Rezolute Trade On?
Rezolute is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Rezolute?
The stock symbol for Rezolute is "RZLT."
What Is the Rezolute Market Cap?
As of today, Rezolute market cap is 344.740M USD.
What Is Rezolute's Earnings Per Share (TTM)?
The Rezolute EPS (TTM) is -0.805.
When Is the Next Rezolute Earnings Date?
Rezolute will release its next earnings report on Sep 10, 2026.
From a Technical Analysis Perspective, Is RZLT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Rezolute Stock Split?
Rezolute has split 3 times.
How Many Employees Does Rezolute Have?
Rezolute has 68 employees.
What is the current trading status of Rezolute (RZLT)?
As of May 28, 2026, Rezolute (RZLT) is trading at a price of 3.270 USD, with a previous close of 3.320 USD. The stock has fluctuated within a day range of 3.225 USD to 3.340 USD, while its 52-week range spans from 1.070 USD to 11.457 USD.
What Is Rezolute (RZLT) Price Target According to Analysts?
The average 12-month price target for Rezolute is 5.875 USD, with a high estimate of 10 USD and a low estimate of 4 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +79.66% Upside potential.
What Is the RZLT Premarket Price?
RZLT's last pre-market stock price is 3.282 USD. The pre-market share volume is 250.000, and the stock has decreased by -0.038, or -1.140%.
What Is the RZLT After Hours Price?
RZLT's last after hours stock price is 3.230 USD, the stock has decreased by -0.040, or -1.220%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.